1. Home
  2. DNTH vs PARR Comparison

DNTH vs PARR Comparison

Compare DNTH & PARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNTH
  • PARR
  • Stock Information
  • Founded
  • DNTH 2015
  • PARR 1984
  • Country
  • DNTH United States
  • PARR United States
  • Employees
  • DNTH N/A
  • PARR N/A
  • Industry
  • DNTH Biotechnology: Pharmaceutical Preparations
  • PARR Integrated oil Companies
  • Sector
  • DNTH Health Care
  • PARR Energy
  • Exchange
  • DNTH Nasdaq
  • PARR Nasdaq
  • Market Cap
  • DNTH 1.5B
  • PARR 1.5B
  • IPO Year
  • DNTH N/A
  • PARR N/A
  • Fundamental
  • Price
  • DNTH $34.50
  • PARR $35.03
  • Analyst Decision
  • DNTH Strong Buy
  • PARR Hold
  • Analyst Count
  • DNTH 10
  • PARR 5
  • Target Price
  • DNTH $66.38
  • PARR $32.00
  • AVG Volume (30 Days)
  • DNTH 947.1K
  • PARR 1.5M
  • Earning Date
  • DNTH 11-06-2025
  • PARR 11-03-2025
  • Dividend Yield
  • DNTH N/A
  • PARR N/A
  • EPS Growth
  • DNTH N/A
  • PARR N/A
  • EPS
  • DNTH N/A
  • PARR N/A
  • Revenue
  • DNTH $4,854,000.00
  • PARR $7,614,628,000.00
  • Revenue This Year
  • DNTH N/A
  • PARR N/A
  • Revenue Next Year
  • DNTH N/A
  • PARR N/A
  • P/E Ratio
  • DNTH N/A
  • PARR N/A
  • Revenue Growth
  • DNTH 17.87
  • PARR N/A
  • 52 Week Low
  • DNTH $13.37
  • PARR $11.86
  • 52 Week High
  • DNTH $40.16
  • PARR $38.60
  • Technical
  • Relative Strength Index (RSI)
  • DNTH 50.57
  • PARR 52.80
  • Support Level
  • DNTH $33.96
  • PARR $33.98
  • Resistance Level
  • DNTH $40.16
  • PARR $36.21
  • Average True Range (ATR)
  • DNTH 2.12
  • PARR 1.56
  • MACD
  • DNTH -0.97
  • PARR -0.34
  • Stochastic Oscillator
  • DNTH 4.03
  • PARR 22.06

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

About PARR Par Pacific Holdings Inc.

Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.

Share on Social Networks: